Morgan Stanley’s VectivBio Holding AG Ordinary Shares VECT Stock Holding History

Morgan Stanley’s Portfolio VECT Stock Details VECT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-31	Closed	-$523	–	7845
2023 Q2	$523	Sell	31 -2,231	-99%	-$29.3K	﹤0.01%	7375
2023 Q1	$19.3K	Hold	2,262	–	–	﹤0.01%	6646
2022 Q4	$19.6K	Hold	2,262	–	–	﹤0.01%	6703
2022 Q3	$13K	Buy	2,262 +2,231	+7,197%	+$12.1K	﹤0.01%	6992
2022 Q2	$0	Hold	31	–	–	﹤0.01%	8125
2022 Q1	$0	Hold	31	–	–	﹤0.01%	8241
2021 Q4	$0	Hold	31	–	–	﹤0.01%	8227
2021 Q3	$0	Buy	+31	New	+$266	﹤0.01%	8096

Other funds holding VECT

RCM

Regency Capital Management Honolulu, Hawaii $224M AUM 26.03% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $844M AUM 37.96% 1-Year Est. Return

Morgan Stanley's VECT Position: Q3 2023 in Review

Morgan Stanley sold out of VectivBio Holding AG Ordinary Shares (VECT) in Q3 2023, closing a stake of 31 shares — an estimated $523 sold.

Morgan Stanley first reported a position in VECT in Q3 2021 and held it in 8 quarters. The position peaked at $19.6K in Q4 2022. 2 funds tracked by Wall St. Rank hold VECT as of Q3 2023.

Morgan Stanley reported no remaining VectivBio Holding AG Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 31 VectivBio Holding AG Ordinary Shares shares in Q3 2023, an estimated $523.
Morgan Stanley first reported a position in VectivBio Holding AG Ordinary Shares in Q3 2021 and held it in 8 quarters.
Morgan Stanley's VectivBio Holding AG Ordinary Shares position peaked at $19.6K in Q4 2022.
2 funds tracked by Wall St. Rank held VectivBio Holding AG Ordinary Shares as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.